All users must agree to the following conditions, in addition to the SOFTWARE TRANSFER AGREEMENT below:

1. All publications based on BRB-ArrayTools analyses will contain the acknowledgment: "Analyses were performed using BRB-ArrayTools developed by Dr. Richard Simon and BRB-ArrayTools Development Team."

2. The package or any of its components will not be distributed to others without prior approval of Dr. Richard Simon.

3. The package is offered without support and the user will not hold the National Cancer Institute, SRA International or the EMMES Corporation liable for any damages resulting from the use of BRB-ArrayTools.

4. The source code is available upon request. To request a copy of the source code, contact Dr. Richard Simon via e-mail (RSimon@nih.gov) or phone (301-496-0975). The source code is provided "as is", without providing any technical support.

Provider: National Cancer Institute

Recipient: The individual's host institution, or the individual him/herself if acting independently
WHEREAS, Provider has certain proprietary software and associated material described below (hereinafter, collectively referred to as "Software"):

Computer software "BRB ArrayTools"

and Provider agrees to transfer such Software to Recipient's investigator, to be used solely in non-commercial research activities (hereinafter noted as "Project").

NOW, THEREFORE, in consideration of the premises and mutual covenants contained herein, the Provider and Recipient agree as follows:

1. Recipient will acknowledge the Provider as the source of the Software in all oral presentations or written publications containing any data or information regarding or resulting from use of the Software.

2. SOFTWARE MAY NOT BE USED FOR TREATING OR DIAGNOSING HUMAN SUBJECTS. Recipient will not license or sell or use Software for commercial purposes or applications. Recipient's investigator shall retain control over Software and further will not transfer the Software to individuals not under Recipient investigator's direct supervision without express advance written approval of Provider. Recipient agrees to comply with all Federal regulations applicable to research projects and handling of research materials.

3. Information deemed confidential under this Agreement shall be clearly marked "CONFIDENTIAL." Any information that is orally disclosed must be reduced to writing and marked "CONFIDENTIAL" by the provider of the information within thirty (30) days of such disclosure. The Computer Software "BRB-ArrayTools" supplied under this Agreement is to be deemed CONFIDENTIAL whether or not it is so marked.

4. To the extent permitted by law, the Recipient agrees to employ all reasonable efforts to safeguard Provider's Confidential Information to ensure that no unauthorized person shall have access thereto and that no unauthorized copy, publication, disclosure or distribution, in whole or in part, in any form shall be made. Such efforts are to be no less than the degree of care employed by Recipient to preserve and safeguard its own confidential information. Confidential Information shall not be disclosed, revealed, or given to anyone except employees who have a need to have the Confidential Information in connection with Project, and who have assumed an obligation to maintain the Confidential Information in confidence at least to the extent that such party is bound hereunder, and such employees shall be advised by such other party of the confidential nature of the Confidential Information and that the Confidential Information shall be treated accordingly. Recipient may publish or otherwise publicly disclose the results of the Project, but if Provider has given Confidential Information to Recipient, such public disclosure may be made only after Provider has had 30 days to review the proposed disclosure, except when a shortened time period under court order or the Freedom of Information Act pertains.

5. The Recipient's obligations under Paragraph 3 shall extend for a period of three (3) years from the date of this Agreement, unless Provider informs Recipient that the Confidential Information is still confidential, in which case the obligations of Paragraph 4 and 5 shall extend for a further period of two (2) additional years.

6. Title in the Software shall remain with the Provider. It is understood that nothing herein shall be deemed to constitute, by implication or otherwise, the grant to either party by the other of any license or other rights under any patent, patent application or other intellectual property right or interest. Provider reserves the right to distribute Software to others and to use it for Provider's own purposes.

7. Upon the request of the Provider, Recipient will destroy or otherwise dispose of the Provider's Confidential Information and all copies of the Provider's Confidential Information.

8. This Agreement may be terminated by either Recipient or Provider upon thirty (30) days advance notice, but the Recipient's obligations under Paragraph 8 will survive such termination.

9. The Provider and Recipient each shall retain title to any patent or other intellectual property of their respective employees developed or created in the course of the Project defined in this Agreement. Neither Provider nor Recipient promise rights in advance for inventions developed under this Agreement.

10. Recipient agrees to hold the United States Government harmless and to indemnify the Government for all liabilities, demands, damages, expenses and losses arising out of Recipient's use for any purpose of Software. Recipient agrees not to claim, infer, or imply Governmental endorsement of the Project, the Recipient or Recipient's personnel conducting the Project or any resulting product(s).

11. Software is supplied AS IS, without any accompanying services or improvements from Provider. SOFTWARE IS SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Provider makes no representations that the use of Software will not infringe any patent or proprietary rights of third parties.

12. The Provider and Recipient acknowledge that they are authorized to enter into this agreement.

13. The illegality or invalidity of any provision of this Agreement shall not impair, affect or invalidate the other provisions of this Agreement.

14. The construction, validity, performance and effect of this Agreement shall be governed by Federal law, as applied by the Federal Courts in the District of Columbia.